Scopus
YÖKSİS Eşleşti
Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia
Clinica Chimica Acta · Ekim 2019
YÖKSİS Kayıtları
Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia
Clinica Chimica Acta · 2019 SCI-Expanded
DOÇENT GÜLSÜM ABUŞOĞLU →
Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia
Clinica Chimica Acta · 2019 SCI-Expanded
PROFESÖR SEDAT ABUŞOĞLU →
Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia
Clinica Chimica Acta · 2019 SCI-Expanded
PROFESÖR ALİ ÜNLÜ →
Makale Bilgileri
DergiClinica Chimica Acta
Yayın TarihiEkim 2019
Cilt / Sayfa497 · 120-124
Scopus ID2-s2.0-85069862665
Özet
Introduction: Imatinib has favorable pharmacokinetic properties, but primary and secondary resistance mechanisms may cause a decrease in clinical response over time. There is a positive correlation between serum imatinib concentrations and treatment response. Our aim was to develop a method for the measurement of imatinib and its' active metabolite N-desmethyl imatinib. Methods: Serum imatinib and N-desmethyl imatinib levels were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and validation studies were carried out according to CLSI (The Clinical & Laboratory Standards Institute) protocols. Serum samples were collected from 40 patients with chronic myeloid leukemia (CML) and analyzed with LC-MS/MS and ultra high-performance liquid chromatography (UHPLC) methods. Results: The linearity range and correlation coefficient were 12.2–12,500 ng/mL and 0.9987 for LC-MS/MS method, respectively. Limit of quantitation was determined as 24.4 ng/mL. The retention times of imatinib and N-desmethyl imatinib were 1.66 and 1.60 min, respectively. There was no statistically significant difference between the results of both methods. Discussion: This LC-MS/MS method is cost-effective and has adavantages such as using low serum volumes, requiring simple pretreatment steps (only protein precipitation) and reduced turnaround times for analysis.
Yazarlar (8)
1
Duygu Eryavuz Onmaz
ORCID: 0000-0001-8564-1824
2
Sedat Abusoglu
ORCID: 0000-0002-2984-0527
3
Ali Ünlü
ORCID: 0000-0002-9991-3939
4
Abdulkadir Basturk
5
Mehmet Dagli
6
M. Bagci
7
Oguzhan Tok
8
Gulsum Abusoglu
Anahtar Kelimeler
Imatinib
Tandem mass spectrometry
Therapeutic drug monitoring
Validation
Kurumlar
Selçuk Tip Fakültesi
Konya Turkey
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
9
Atıf
8
Yazar
4
Anahtar Kelime